Suijkerbuijk, Karijn P. M. http://orcid.org/0000-0003-3604-5430
van Eijs, Mick J. M. http://orcid.org/0000-0002-9763-6704
van Wijk, Femke
Eggermont, Alexander M. M.
Article History
Received: 31 August 2023
Accepted: 12 January 2024
First Online: 15 February 2024
Competing interests
: K.P.M.S. has advisory relationships with Bristol Myers Squibb, Novartis, MSD, Pierre Fabre and AbbVie and has received honoraria from Novartis, MSD and Sairopa and research funding from BMS, Philips and TigaTx, all paid to the institution. F.v.W. has received advisory and/or speaker fees from Takeda and Johnson & Johnson and research funding from BMS, Takeda, Sanofi, Pfizer, Galapagos and Leo Pharma. A.M.M.E. has received honoraria for advisory relationships from Agenus, Boehringer Ingelheim, BioInvent, BioNTech, Brenus, CatalYm, Epics, GenOway, IO Biotech, IQVIA, ISA Pharmaceuticals, Merck & Co/MSD, Oncimmune, Pfizer, Pierre Fabre, Sairopa, Sellas, Scorpion, SkylineDX, TigaTx and Trained Therapeutics and moreover speaker fees from BMS and MSD and has equity in IO Biotech, Sairopa and SkylineDX. No potential conflicts of interest were disclosed by M.J.M.v.E.